ERBB2 and breast carcinoma: Recent years, cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i), including palbociclib and ribociclib, have been used for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor-negative (HER2-) advanced breast cancer (ABC) (2, 3).